Author

Udi Segal

Genentech

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Alexis ScherliD· 1 shared Amy Shelton· 1 shared Andrew Goetz· 1 shared Bartosz CzechiD· 1 shared Cecile C. de la Cruz· 1 shared Charisa CottonhamiD· 1 shared Chris Siebel· 1 shared Ciara MetcalfeiD· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexis ScherlORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Notch signaling maintains a progenitor-like subclass of hepatocellular carcinoma

Kerstin Seidel, Robert Piskol, Thi Thu Thao Nguyen, Amy Shelton, Charisa Cottonham, Cecile C. de la Cruz, Joseph Castillo, Jesse Garcia, Udi Segal, Mark A. Merchant, Yeqing Angela Yang, Jasmine Chen, Musa Ahmed, Alexis Scherl, Rajesh Vij, , Chris Siebel

This study identifies Notch-dependent progenitor-like HCCs that regress upon Notch inhibition, revealing a therapeutic target in a poor-prognosis subgroup.

bioRxiv · Dec 13, 2024 · PreprintCancer Biology

Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma

Andrew Goetz, Frances Shanahan, Logan Brooks, Eva Lin, Rana M Mroue, Darlene Dela Cruz, Thomas Hunsaker, Bartosz Czech, Purushottam D. Dixit, Udi Segal, Scott E. Martin, Scott A. Foster, Luca Gerosa

This study uses computational modeling and preclinical data to identify optimal dosing strategies for panRAF and MEK inhibitors in melanoma, revealing distinct dose requirements based on NRAS vs BRAF mutations.

Cancers · Aug 22, 2024Peer-reviewedSystems Biology